







## NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

### **AGENDA 35**

Time & Date: 4pm - 4.30 pm Tuesday April 5 2022

Venue: Via Teams

Host: API

Attendees: Symbion Symbion

Sigma Healthcare **National Pharmacies** 

**Apologies:** - NPSA Executive Director

1	Welcome – apologies - Reminder of meeting purpose and conduct as per ACCC temporary authorisation - Review of the previous minutes for March 2022 – refer to Attachment A	RT ALL
2	Trends in supply and demand of medicines  - General discussion by all members on trends and observations over the previous month with focus on any new spikes in cases as restrictions ease	ALL
3	Specific medicines at risk – NEW  General discussion by all members on any NEW medicines identified or have been placed under a new DoH Written Direction	ALL
4	Specific medicines at risk – EXISTING  - General discussion by all members on existing medicines placed on restriction:	ALL
5	Reporting	









	<ul> <li>TGA Reporting</li> <li>Update on ACCC Authorisation and associated reporting – no further update</li> </ul>	ALL For Noting
6.	Other Business	
	<ul> <li>Living with COVID – general discussion</li> <li>COVID Vaccine Distribution update</li> </ul>	ALL ALL









### **Attachment A**

# NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

### Minutes 34

**Time & Date:** 4.00 pm – 4.30 pm Tuesday,8 March 2022

Venue: Via Teams

**Host:** – NPSA Executive Director

Attendees: Symbion

Sigma Healthcare

NPD

API

Apologies: Symbion

ITEM	DISCUSSION AREA	ACTION AGREED
1	Welcome  - meeting purpose and conduct as per ACCC authorisation was discussed.	Noted and accepted
	- Minutes from the February 2022, meeting accepted	Minutes Accepted
2	Trends in supply and demand of medicines     All members commented that over the last four weeks there has been no new or abnormal demand or signs of concern regarding potential stockpiling behaviour nationally or locally	All members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern
3	<ul> <li>Specific medicines at risk – NEW</li> <li>Members reported a need to watch all lines of the immediate weeks due to indicative trends in global shortages</li> </ul>	Noted and all members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern









4	Specific medicines at risk – EXISTING  - All members are managing under the current Written Direction the following medicine:	Noted and being actioned
5	- Update on TGA Reporting –  - Update on ACCC Authorisation – reporting from next month will move to monthly as opposed to fortnightly	Noted Noted
6	- Living with COVID – no further update - COVID Vaccine Distribution – no further update -	Noted  Noted and members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern  Noted and
	- RAT Kit Supply –	members to action
	Next meeting – Tuesday April 5, 4pm – 5 pm	









# NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

### Minutes 35

Time & Date: 4pm - 4.20 pm Tuesday April 5 2022

Venue: Via Teams

Host: API

Attendees: Symbion Symbion

**National Pharmacies** 

**Apologies:** - NPSA Executive Director Sigma Healthcare

1.	Welcome – apologies - Reminder of meeting purpose and conduct as per ACCC temporary authorisation was discussed	Noted and accepted
	- Minutes from the February 2022, meeting accepted	Minutes approved
2	Trends in supply and demand of medicines  - All members agreed that in the last month there has been no new or abnormal demand or signs of concern regarding potential stockpiling behaviour nationally or locally	All members to watch ordering behaviour closely and report back into the group immediately if they detect any areas of concern
3	- All agreed that restrictions are now in place with all members as per CSO directive for	Noted – no further action









	Next Meeting: May 3, 2022 – 4pm – 5pm	
	<ul> <li>Living with COVID – no further update</li> <li>COVID Vaccine Distribution update – no further update</li> </ul>	Noted Noted
<ul><li>5</li><li>6.</li></ul>	Reporting  - TGA Reporting remains the same status as prior meetings  - Update on ACCC Authorisation and associated reporting – no further update  Other Business	Noted Noted
4	<ul> <li>Specific medicines at risk – EXISTING         <ul> <li>Members continue to manage medicines under previous CSO written directions:</li> <li>No further change from the last meeting in regard to purchasing behaviour</li> </ul> </li> </ul>	Noted and monitoring